1 min read

ID: 780729

Short Link: https://gregory-ms.com/articles/780729/

Discovery Date: 27 July 2022, 11:15:07 UTC

Published Date: 2022-07-27 10:00:00

Source: PubMed

Link: https://pubmed.ncbi.nlm.nih.gov/35890315/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20220727071506&v=2.17.7

Manual Selection: true

Machine Learning Gaussian Naive Bayes Model: false

Abstract

Lysine specific demethylase 1 (LSD1; also known as KDM1A), is an epigenetic modulator that modifies the histone methylation status. KDM1A forms a part of protein complexes that regulate the expression of genes involved in the onset and progression of diseases such as cancer, central nervous system (CNS) disorders, viral infections, and others. Vafidemstat (ORY-2001) is a clinical stage inhibitor of KDM1A in development for the treatment of neurodegenerative and psychiatric diseases. However, the…

Noun Phrases in Title

  • Efficacy
  • Vafidemstat
  • Experimental Autoimmune Encephalomyelitis
  • Highlights
  • the KDM1A/RCOR1/HDAC Epigenetic Axis
  • Multiple Sclerosis
This is an independent project that runs on the good will of volunteers

You can help by spreading the word or by donating what you can to pay for the server costs.